What is indication splitting licensing in pharmaceutical and bio-pharmaceutical business?
Posted on30 Sep 2019
Comments0
While licensing in pharmaceutical and bio pharmaceutical business, if licenses are issued to different partners based on indications or disease and therapy,... Read More
Bactiguard entered Licensing deal for Orthorthopedic trauma implants with Zimmer Biomet
Bactiguard, a Swedish medical device company with a mission to increase patient safety and save lives, has entered into an exclusive, global... Read More
AstraZeneca to launch QTERN in India with DCGI marketing authorization approval
Posted on27 Sep 2019
Comments0
AstraZeneca Pharma has received import and market permission in Form 45 (marketing authorization) for QTERN (fixed dose combination of dapagliflozin 10mg +... Read More
FDA approved Rybelsus (semaglutide): first oral GLP-1 treatment for type 2 diabetes
Posted on25 Sep 2019
Comments0
The U.S. Food and Drug Administration today approved Rybelsus (semaglutide) oral tablets to improve control of blood sugar in adult patients with... Read More
Bayer received EU marketing authorization for the precision oncology treatment Vitrakvi (larotrectinib)
Bayer announced that the European Commission has granted marketing authorization in the European Union (EU) for the precision oncology treatment Vitrakvi (larotrectinib).... Read More
Clovis in-licensing deal for cancer program from 3B Pharmaceuticals
Clovis Oncology inks an agreement with privately held 3B Pharmaceuticals GmbH for global rights (ex. Europe, Russia, Turkey and Israel) to a... Read More
Biocon Ltd acquired a R&D facility from Pfizer
Posted on25 Sep 2019
Comments0
Biocon Ltd has acquired a Chennai-based research and development (R&D) facility from Pfizer Healthcare India Ltd through its subsidiary Biocon Biologics. The... Read More
Pharma acquisition case study: Lundbeck to acquire Alder BioPharmaceuticals for US$ 1.95 billion
H. Lundbeck A/S (Lundbeck) and Alder BioPharmaceuticals (Alder) announced a definitive agreement for Lundbeck to acquire Alder. About the deal: Under the... Read More
Insight on submission of USFDA sBLA of Tremfya (guselkumab) for the treatment of adult patients with active psoriatic arthritis (PsA)
Posted on18 Sep 2019
TagsJanssen, Janssen Biotech, Janssen Pharma, MorphoSys AG, sBLA, supplemental Biologics License Application, Tremfya
Comments0
MorphoSys AG, a clinical-stage biopharmaceutical company, announced that its licensee Janssen Research & Development, submitted a supplemental Biologics License Application (sBLA) to... Read More
Mitsubishi Tanabe Pharma, Daiichi Sankyo enters licensing agreement for ALS treatment agent edaravone in Brazil
Posted on18 Sep 2019
Comments0
Mitsubishi Tanabe Pharma Corporation and Daiichi Sankyo announced that they have concluded a licensing agreement covering commercialization rights in Brazil for an... Read More